Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 5341 AL 5355

Targeting the mTOR signaling network for Alzheimer's disease therapy

Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L.

Mol Neurobiol. 2014 Feb;49(1):120-35. doi: 10.1007/s12035-013-8505-8. Epub 2013 Jul 14.

Update on Alzheimer's disease therapeutics

Rafii MS.

Rev Recent Clin Trials. 2013 Jun;8(2):110-8. doi: 10.2174/15748871113089990045.

Therapeutic potential of turmeric in Alzheimer's disease: curcumin or curcuminoids?

Ahmed T, Gilani AH.

Phytother Res. 2014 Apr;28(4):517-25. doi: 10.1002/ptr.5030. Epub 2013 Jul 19.

Novel γ-secretase modulators for the treatment of Alzheimer's disease: a review focusing on patents from 2010 to 2012

Pettersson M, Stepan AF, Kauffman GW, Johnson DS.

Expert Opin Ther Pat. 2013 Oct;23(10):1349-66. doi: 10.1517/13543776.2013.821465. Epub 2013 Jul 23.

Dual inhibitors of monoamine oxidase and cholinesterase for the treatment of Alzheimer disease

Yáñez M, Viña D.

Curr Top Med Chem. 2013;13(14):1692-706. doi: 10.2174/15680266113139990120.

Therapeutics of Alzheimer's disease: Past, present and future

Anand R, Gill KD, Mahdi AA.

Neuropharmacology. 2014 Jan;76 Pt A:27-50. doi: 10.1016/j.neuropharm.2013.07.004. Epub 2013 Jul 25.

Mitochondrial filamentation: a therapeutic target for neurodegeneration and aging

Gosalvez M.

Am J Alzheimers Dis Other Demen. 2013 Aug;28(5):423-6. doi: 10.1177/1533317513494451.

Who is that stranger in the mirror? The mirror experience for elderly patients with dementia

Kelsick JR, Freysteinson WM.

Holist Nurs Pract. 2013 Sep-Oct;27(5):268-72. doi: 10.1097/HNP.0b013e31829b924a.

Comparison of ELISA measurements of anti-Aβ concentrations and percentages of specific binding to Aβ between unfractionated intravenous immunoglobulin products and their purified anti-Aβ antibodies

Klaver AC, Coffey MP, Smith LM, Loeffler DA.

Immunol Lett. 2013 Jul-Aug;154(1-2):7-11. doi: 10.1016/j.imlet.2013.07.008. Epub 2013 Aug 6.

The multifactorial nature of Alzheimer's disease for developing potential therapeutics

Carreiras MC, Mendes E, Perry MJ, Francisco AP, Marco-Contelles J.

Curr Top Med Chem. 2013;13(15):1745-70. doi: 10.2174/15680266113139990135.

Emerging targets in neurodegeneration: new opportunities for Alzheimer's disease treatment?

Rampa A, Gobbi S, Belluti F, Bisi A.

Curr Top Med Chem. 2013;13(15):1879-904. doi: 10.2174/15680266113139990143.

Natural products as sources of new lead compounds for the treatment of Alzheimer's disease

Huang L, Su T, Li X.

Curr Top Med Chem. 2013;13(15):1864-78. doi: 10.2174/15680266113139990142.

From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach

Calzà L, Baldassarro VA, Giuliani A, Lorenzini L, Fernandez M, Mangano C, Sivilia S, Alessandri M, Gusciglio M, Torricella R, Giardino L.

Curr Top Med Chem. 2013;13(15):1843-52. doi: 10.2174/15680266113139990140.

Dual inhibitors of β-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates

Viayna E, Sabate R, Muñoz-Torrero D.

Curr Top Med Chem. 2013;13(15):1820-42. doi: 10.2174/15680266113139990139.

Lessons learnt from glycogen synthase kinase 3 inhibitors development for Alzheimer's disease

Martinez A, Perez DI, Gil C.

Curr Top Med Chem. 2013;13(15):1808-19. doi: 10.2174/15680266113139990138.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias